Nuvectis Pharma, Inc.
NVCT
$8.76
-$0.04-0.46%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 31.63M | 35.44M | 26.79M | 29.86M | 18.53M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | -- | -- | -- | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 75.00K | 145.00K | 214.00K | 284.00K | 74.00K |
| Total Current Assets | 31.71M | 35.59M | 27.01M | 30.15M | 18.61M |
|
|
|||||
| Total Current Assets | 31.71M | 35.59M | 27.01M | 30.15M | 18.61M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | -- | -- | -- | -- |
| Total Assets | 31.71M | 35.59M | 27.01M | 30.15M | 18.61M |
|
|
|||||
| Total Accounts Payable | 6.27M | 6.44M | 4.98M | 2.99M | 2.50M |
| Total Accrued Expenses | 7.02M | 5.06M | 5.08M | 5.90M | 6.40M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | -- | 75.00K | 75.00K | 300.00K | -- |
| Total Other Current Liabilities | -- | 75.00K | 75.00K | 300.00K | -- |
| Total Current Liabilities | 13.30M | 11.58M | 10.14M | 9.19M | 8.89M |
|
|
|||||
| Total Current Liabilities | 13.30M | 11.58M | 10.14M | 9.19M | 8.89M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 13.30M | 11.58M | 10.14M | 9.19M | 8.89M |
|
|
|||||
| Common Stock & APIC | 118.10M | 116.38M | 101.78M | 99.53M | 82.96M |
| Retained Earnings | -99.69M | -92.37M | -84.91M | -78.58M | -73.25M |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | 18.41M | 24.01M | 16.87M | 20.95M | 9.71M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 18.41M | 24.01M | 16.87M | 20.95M | 9.71M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 18.41M | 24.01M | 16.87M | 20.95M | 9.71M |
|
|
|||||